Fundraising Fox

Celularity

NASDAQ: CELU

Florham Park, US · Founded 2018 · Delaware corporation · 3 known investors

Celularity is a regenerative and cellular medicine company developing and commercializing biomaterial products and allogeneic, cryopreserved cell therapies derived from the postpartum placenta to target age-related diseases. It operates its own integrated manufacturing, translational research, and biobanking facility for placenta-derived cellular medicines and advanced biomaterials.

BiotechHealthtechLongevity

Founders & leadership

Celularity was founded in 2018 by Robert J. Hariri.

RJ
Robert J. HaririFounder
JD
Joseph DosSantosChief Financial Officer
JR
John R. HainesExecutive
SA
Stephen A. BrigidoPresident, Degenerative Disease
BG
Bradley GloverExecutive
AL
Andrew L. PecoraExecutive
LK
Lim Kok ThayNamed on SEC filing
JS
John SculleyNamed on SEC filing
RL
Robin L. SmithNamed on SEC filing
DC
David C. BeersNamed on SEC filing
MM
Marc MazurNamed on SEC filing

Board

PDPeter Diamandis
Peter Diamandisin𝕏Board directorPhysician, entrepreneur, and futurist inspiring leaders to think exponentially and create a future of abundance

Investors · 3

Blue Ivy VenturesBoston
Castor Ventures (an Alumni Ventures Fund)
Bold Capital PartnersreportedSanta Monicavia Peter Diamandis · board

Reported raises · per SEC filings

Form D private placements

$41.8M disclosed across 5 rounds · 2022–2025

▶$2MraisedNov 2025 · 1 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Diane ParksDirector
  • Peter DiamandisDirector
  • John R. HainesExecutive Officer
  • Vincent LeVienDirector
  • Joseph DosSantosExecutive Officer
  • Robert J. HaririExecutive Officer, Director
  • Geoffrey LingDirector
  • Stephen A. BrigidoExecutive Officer
Offering amount
$6.7M
Amount sold
$2M
First sale
Oct 2025
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$2MraisedAug 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert J. HaririExecutive Officer, Director
  • Stephen A. BrigidoExecutive Officer
  • John R. HainesExecutive Officer
  • Diane ParksDirector
  • Vincent LeVienDirector
  • Peter DiamandisDirector
  • Joseph DosSantosExecutive Officer
  • Geoffrey LingDirector
Offering amount
$2M
Amount sold
$2M
First sale
Jul 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.8MraisedAug 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Vincent LeVienDirector
  • Robert J. HaririExecutive Officer, Director
  • Joseph DosSantosExecutive Officer
  • Peter DiamandisDirector
  • John R. HainesExecutive Officer
  • Geoffrey LingDirector
  • Stephen A. BrigidoExecutive Officer
  • Diane ParksDirector
Offering amount
$6.8M
Amount sold
$6.8M
First sale
Jul 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedAug 2025 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter DiamandisDirector
  • Diane ParksDirector
  • Geoffrey LingDirector
  • Robert J. HaririExecutive Officer, Director
  • Stephen A. BrigidoExecutive Officer
  • John R. HainesExecutive Officer
  • Joseph DosSantosExecutive Officer
  • Vincent LeVienDirector
Offering amount
$1M
Amount sold
$1M
First sale
Jul 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30MraisedMay 2022 · 1 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Bradley GloverExecutive Officer
  • Andrew L. PecoraExecutive Officer
  • Lim Kok ThayDirector
  • John SculleyDirector
  • Dean C. KehlerDirector
  • Robin L. SmithDirector
  • Peter DiamandisDirector
  • John R. HainesExecutive Officer
  • Andrew C. von EschenbachDirector
  • David C. BeersExecutive Officer
  • Marc MazurDirector
  • Jay BloomDirector
  • Robert J. HaririExecutive Officer, Director
  • Keary DunnExecutive Officer
  • Stephen A. BrigidoExecutive Officer
  • Anne JonesExecutive Officer
Offering amount
$30M
Amount sold
$30M
Sales commissions
$2.1M
Placement agents
A.G.P/ Alliance Global Partners
First sale
May 2022
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap
Cellarity30 shared keywordsCellarity develops therapeutics using AI-powered multi-omics analysis to identify and correct dysfunctional cellular states, treating complex diseases by regulating genetic pathways rather than targeting single genes.
Kite Pharma28 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Cellares26 shared keywordsCellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies. The company serves biopharmaceutical manufacturers and cell therapy developers worldwide.

Companies competing with Celularity for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Celularity do?
Celularity is a regenerative and cellular medicine company developing and commercializing biomaterial products and allogeneic, cryopreserved cell therapies derived from the postpartum placenta to target age-related diseases. It operates its own integrated manufacturing, translational research, and biobanking facility for placenta-derived cellular medicines and advanced biomaterials.
Who founded Celularity?
Celularity was founded by Robert J. Hariri in 2018.
Who are Celularity's investors?
Celularity's investors include Blue Ivy Ventures, Castor Ventures (an Alumni Ventures Fund), Bold Capital Partners.
How much funding has Celularity raised?
Celularity has disclosed $41.8M raised across 5 rounds.
Where is Celularity headquartered?
Celularity is headquartered in Florham Park, US.
Celularity — Investors & Founders | Fundraising Fox